Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an open label phase I/II trial to determine the safety and the biologic activity of
the bendamustine, bortezomib and pegylated liposomal doxorubicin combination.